- Topics
- Regions
- Events
- Webcasts
- Resources
- CW Exclusives
- Membership
“For tracking litigation, enforcement, and regulatory developments, Compliance Week
should be your prime source.”- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
Lease Accounting Solution Transition (LAST) Planner
Provided by 
Visual Lease2021-01-27T12:43:00
Many public companies chose a lease accounting solution to satisfy their immediate compliance needs – without fully understanding the importance of managing their leases.
The Lease Accounting Solution Transition (LAST) Planner is a (2-step) tool that helps companies evaluate how to switch from their existing lease accounting platform to another.After helping many clients switch systems, Visual Lease developed processes and best practices to make the transition smooth and efficient.
Get what you need to make the switch – including milestones for you and your team and resources to help you nail every step in the process.
Sponsored resource
This resource has been prepared by our sponsor and is free to view.
How to view
You need to register for this site and agree to the sponsor’s conditions to be granted access.
Related articles
-
NewsCannabis company dinged by SEC over ‘round-trip’ transfer to inflate year-end cash
A cannabis company agreed to pay $225,000 to settle allegations that funds were temporarily deposited into its year-end accounts for the sole purpose of inflating year-end cash, the Securities and Exchange Commission said.
-
News BriefSEC slams WWE founder Vince McMahon for misstatements caused by hush money payments
Vince McMahon, the founder and former CEO of WWE, was fined $400,000 and ordered to reimburse the wrestling giant more than $1.3 million to settle charges brought by the Securities and Exchange Commission that he failed to disclose hush money payments he made on behalf of himself and the company.
-
News BriefBecton Dickinson pays $175M for misleading investors about flawed IV pump system
Becton Dickinson medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission said.